Approval · Notice of Compliance 4178 · 1996
ENTROPHEN: Notice of Compliance 4178
Issued March 1, 1996
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4178
- Date
- March 1, 1996
- Company
- Merck Frosst Canada Inc.Kirkland, QC, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Provides for reducing the risk of morbidity and death in patients with unstable angina and in those with previous myocardial infarction
- Therapeutic class
- Nonsteroidal anti-inflammatory, analgesic, platelet aggregation inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENTROPHEN | Not yet assigned | — |
Medicinal ingredients
- ACETYLSALICYLIC ACID 325 MG per TAB